Compounded Tirzepatide

GLP-1 Weight Loss

Choose a treatment option

Subcutaneous Injection

Precise, reliable dosing; ideal for peptides that can't survive digestion

From $199/mo

Tirzepatide is a first-in-class "dual agonist" that mimics two naturally occurring metabolic hormones: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP).

Check eligibility

While FDA-approved under brand names like Mounjaro® and Zepbound® for diabetes and chronic weight management, compounded Tirzepatide is utilized to meet specific patient needs or bridge supply shortages. Tirzepatide is not FDA-approved to diagnose, treat, or cure any disease other than those specifically indicated on your prescription.

Why it works

Key benefits

Significant Weight Reduction: Clinical data (SURMOUNT trials) show substantial weight loss when combined with a reduced-calorie diet and increased physical activity.

Improved Glycemic Control: Effective stabilization of HbA1c and fasting blood glucose levels.

Metabolic Health: Support for healthy blood pressure, cholesterol levels, and waist circumference.

Appetite Suppression: Notable reduction in "food noise" and cravings for high-calorie foods.

Based on clinical trials

Mechanism

How it works

Tirzepatide is often referred to as a "Twincretin" because of its dual-action mechanism which provides more comprehensive metabolic support than GLP-1-only medications: GIP Receptor Activation: Enhances insulin secretion and helps regulate fat metabolism, which may contribute to better weight loss results and fewer gastrointestinal side effects for some patients. GLP-1 Receptor Activation: Slows gastric emptying (keeping you full longer) and signals the brain’s satiety centers to reduce food cravings. Blood Sugar Regulation: Collaboratively helps the pancreas release insulin more effectively and reduces the liver’s production of excess glucose.

Frequently asked questions

FAQs

Patients typically notice a reduction in appetite within the first 24–72 hours of the first dose. Because the medication follows a titration schedule, the most significant weight loss results usually occur between months 3 and 6 as you reach higher doses.

Side effects are primarily gastrointestinal and usually temporary: Nausea, vomiting, or diarrhea. Heartburn, acid reflux, or abdominal bloating. Constipation. Injection site reactions (redness or itching).

Before you begin

Informed Consent & Safety

Important: Report persistent severe abdominal pain, persistent vomiting, or signs of an allergic reaction to your clinician immediately.

Research & Studies

Evidence at a Glance

1.
Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
2.
Frías, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.
3.
Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes (SURPASS-1). The Lancet.
4.
Heise, T., et al. (2022). Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care.

Interested in Compounded Tirzepatide?

Take a short assessment and a licensed provider will review if this treatment is right for you.

Check eligibility

Clinical Guidance Disclaimer

The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.

Liability & Indemnification

By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.

Regulatory Status

Compounded Tirzepatide is prepared by licensed 503A or 503B pharmacies. While the active ingredient is FDA-approved in commercial brands, the compounded version itself is not independently FDA-approved.

Proprietary Rights & Use Restrictions

This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.